ArticleVeterinary world2025
Validated RP-HPLC based characterization of synergistic antibacterial, antioxidant, and anticancer activities of combined mangosteen pericarp and turmeric extracts.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Mangosteen ( Materials and Methods: Ultrasound-assisted extraction was employed to prepare ethanolic extracts. Antibacterial activities were assessed using disk diffusion, minimum inhibitory concentration (MIC), and minimum bactericidal concentration assays against five bacterial strains, with synergy evaluated through checkerboard fractional inhibitory concentration index. Antioxidant activity was measured by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging and total phenolic content (TPC). Cytotoxicity was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays on human hepatocellular carcinoma cells (HepG2), human breast adenocarcinoma cells (MCF-7), and human normal fibroblast cells. A reversed-phase HPLC method was developed and validated to simultaneously quantify α-mangostin and curcumin in the combined extract. Results: Mangosteen and turmeric extracts showed MICs of 3.12 and 31.25μg/mL, respectively. Combined extracts demonstrated additive or synergistic effects against Gram-positive bacteria and enhanced the efficacy of gentamicin (up to 19-fold MIC reduction). The combined extract exhibited the strongest antioxidant activity (half-maximal inhibitory concentration = 5.78 μg/mL) and highest TPC (1227.38 mg gallic acid equivalent/g extract). Cytotoxic assays revealed selective inhibition of HepG2 and MCF-7 cells, with no toxicity toward normal fibroblasts. The validated HPLC method enabled accurate, simultaneous quantification of curcumin (73.23mg/g extract) and α-mangostin (146.80mg/g extract) with excellent linearity (R Conclusion: The combination of mangosteen and turmeric extracts exhibits potent, selective, and synergistic antibacterial and anticancer properties, along with enhanced antioxidant capacity. The validated HPLC method provides a reliable tool for quality control and standardization of such polyherbal formulations, supporting their potential for therapeutic and veterinary applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.